Phase 2 N=53 Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
Lymphoma
Primary: 3 Year Progression-Free Survival Rate — 30 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=39 Open-Label Study of OTO-201 for Treatment of AOMT
Acute Otitis Media · AOMT
Primary: Number of Ears With Otorrhea (Drainage From the Middle Ear) — 8 affected ears
Phase 3 N=224 A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
Tuberous Sclerosis Complex · Seizures
Primary: Percent Change From Baseline in the Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures During the Treatment Period (Maintenance and Titration) — -43.36…
Phase 2 N=19 Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
Primary: Number of Participants With Drug-Related Serious Adverse Events (SAEs) — 0 Participants
N/A N=23 A Bilateral Dispensing Clinical Trial of an Sapphire Lens Against Senofilcon A Toric for Astigmatism Lens
Astigmatism
Primary: Subjective Ratings for Comfort — 89; 80 units on a scale
Phase 2 N=2 Renal Allograft Tolerance Through Mixed Chimerism
End Stage Renal Disease
Primary: Successful Withdrawal of Immunosuppressive Therapy — 2 Participants
Phase 1 N=30 Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma
Composite Lymphoma · Grade 3b Follicular Lymphoma · Stage I Diffuse Large B-Cell Lymphoma
Primary: Number of Participants With a Grade 3 or Higher Toxicity Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 — 13…
Phase 2 N=210 Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne Vulgaris
Acne Vulgaris
Primary: Absolute Change From Baseline in Mean Noninflammatory Lesion Count to Week 12 — -21.6; -20.3; -13.1 lesions
Phase 2 N=233 Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin
Pruritus
Primary: Worst Itch Numeric Rating Scale 4-point Responder Rate at Week 10 — 46; 44 Participants — p=0.5861
Phase 3 N=379 A Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation
Head Lice Infestation
Primary: Proportion of Index Subjects Who Are Lice-free at All Follow-up Visits Through to the Day 14 Visit. — 43; 28 participants
Phase 2 N=133 A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Primary: Progression Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Investigator Radiologic Review — 2.9; 5.7…
N/A N=124 Enhancing Survivorship Care Planning for Patients With Localized Prostate Cancer Using A Couple-focused Web-based Tailored Symptom Self-management Program
Prostate Cancer
Primary: Percentage of Potentially Eligible Participants Actually Enrolled Into the Study — 62 dyad
N/A N=84 Stereotactic Body Radiotherapy for Prostate Cancer
Prostate Cancer
Primary: Biochemical Control Rate — 71; 0 Participants
Phase 3 N=33 Open-Label Study of OTO-201 for Middle Ear Effusion Evaluating Trans-Tympanostomy Tube Administration
Bilateral Middle Ear Effusion
Primary: Otoscopic Examination: Auricle and Meatus — 1 ears
N/A N=195 De Por Vida: A Diabetes Risk Reduction Intervention for Hispanic Women
Diabetes · Weight Loss · PreDiabetes
Primary: Weight in Kilograms — 87.1; 86.3; 84.4; 85.9 kilograms — p==.001